PMID- 37954782
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231114
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 10
DP  - 2023 Oct
TI  - The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and 
      Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian 
      Population.
PG  - e46767
LID - 10.7759/cureus.46767 [doi]
LID - e46767
AB  - Introduction Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder 
      affecting millions of individuals worldwide. Effective management of T2DM is 
      crucial to prevent complications. Dapagliflozin and sitagliptin are oral 
      anti-diabetic agents that have been shown to provide synergistic effects in 
      controlling blood glucose levels. However, there is limited data on the efficacy 
      and safety of the dapagliflozin-sitagliptin fixed-dose combination (FDC) in the 
      Indian population. This study aimed to evaluate the real-world effectiveness and 
      safety of the dapagliflozin-sitagliptin FDC in the Indian population. Methods 
      This was a retrospective study conducted at healthcare centers in India. The 
      study included patients with T2DM who were prescribed a FDC of dapagliflozin and 
      sitagliptin. Data were collected from the medical health records of patients, 
      including demographics, baseline glycated hemoglobin (HbA1c), blood glucose 
      levels, BMI, blood pressure, and adverse events. The primary outcome was the 
      change in HbA1c, postprandial plasma glucose (PPG), and fasting plasma glucose 
      (FPG) from baseline to 12 weeks after treatment initiation. Results A total of 
      358 patients were included in the study, with a mean age of 56.2 years. The 
      majority of the patients were male (68.2%), and the mean baseline HbA1c was 8.9 +/- 
      0.87%. After 12 weeks of treatment with dapagliflozin and sitagliptin, there was 
      a significant reduction in HbA1c levels from 8.9 to 7.2 (p <0.0001). There was 
      also a significant reduction in fasting blood glucose levels from 178.8 to 124.0 
      (p <0.0001) and postprandial blood glucose levels from 273.9 to 176.0 (p 
      <0.0001). There were no serious adverse events reported during the study period. 
      Conclusion The FDC of dapagliflozin and sitagliptin is effective and safe in 
      reducing blood glucose levels and BMI in the Indian population with T2DM. This 
      real-world retrospective study provides valuable insights into the clinical 
      effectiveness and safety of dapagliflozin-sitagliptin FDC in the Indian 
      population. These findings highlight the potential benefits of this combination 
      therapy in managing T2DM and pave the way for optimized treatment strategies and 
      improved patient outcomes in the Indian healthcare landscape. Clinicians may 
      consider dapagliflozin-sitagliptin FDC as a viable treatment option for T2DM 
      patients.
CI  - Copyright (c) 2023, Bhattacharjee et al.
FAU - Bhattacharjee, Rana
AU  - Bhattacharjee R
AD  - Endocrinology, Diabetes and Metabolism, Institute of Post Graduate Medical 
      Education & Research, Kolkata, IND.
FAU - Rai, Madhukar
AU  - Rai M
AD  - Medicine, Heritage Institute of Medical Sciences, Varanasi, IND.
FAU - Joshi, Priyanka
AU  - Joshi P
AD  - Medical Affairs, USV Private Limited, Mumbai, IND.
FAU - Prasad, Ashish
AU  - Prasad A
AD  - Scientific Services, USV Private Limited, Mumbai, IND.
FAU - Birla, Ashish
AU  - Birla A
AD  - Scientific Services, USV Private limited, Mumbai, IND.
LA  - eng
PT  - Journal Article
DEP - 20231009
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10632527
OTO - NOTNLM
OT  - dapagliflozin
OT  - diabetes mellitus
OT  - fixed-dose combination
OT  - indian population
OT  - real-world study
OT  - sitagliptin
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2023/11/13 06:43
MHDA- 2023/11/13 06:44
PMCR- 2023/10/09
CRDT- 2023/11/13 04:37
PHST- 2023/10/07 00:00 [accepted]
PHST- 2023/11/13 06:44 [medline]
PHST- 2023/11/13 06:43 [pubmed]
PHST- 2023/11/13 04:37 [entrez]
PHST- 2023/10/09 00:00 [pmc-release]
AID - 10.7759/cureus.46767 [doi]
PST - epublish
SO  - Cureus. 2023 Oct 9;15(10):e46767. doi: 10.7759/cureus.46767. eCollection 2023 
      Oct.